Creative Biolabs is a leading service provider that focuses on mRNA (messenger ribonucleic acid)-based studies for years. By combining cutting edge technologies with proprietary innovations, scientists at Creative Biolabs provides a full range of mRNA therapeutics development services based on new TriMix technology. Our technology provides a broadly applicable combination treatment for a wide range of disease types. Nowadays, we are committed to bringing deep domain expertise to assist our clients in achieving their strategic and operational objectives.
Dendritic cells (DCs) are a group of immune cells that play an important role in preventing the human body from viruses and cancers. DCs can help the activation of immune responses and inhibit the growth of abnormal cells. DCs are a type of antigen-presenting cells (APCs), which can also be used for activating naive T cells. Normally, DCs are derived from bone marrow and can exist many portions of the human body, such as the skin. Immature DCs can present a variety of viral or bacterial antigens based on MHC class I and II complexes. These infections can induce the generation of viral or bacterial products to trigger the signal of DC maturation. Moreover, DCs can interact with different kinds of T cells, including CD8+ cytotoxic T cells and CD4+ helper T cells, to cause specific cellular immune responses against diseases or infections.
Currently, various DCs have been used in the development of cancer vaccine and novel immunotherapies. Meanwhile, a panel of assays has been established for loading DC with various tumors or viral antigens. Among them, mRNA-transfected DCs have become a popular method for load DC with different tumor antigens to induce strong cellular immunity. However, mRNA-based assays are insufficient in stable and high-level expression in target cells. As a result, novel technologies still need to be designed for improving mRNA-transfected DCs-based immune responses in a more specific and effective way.Fig.1 Maturation induction and antigen loading in a one-step procedure. (Van, 2014)
In the past few years, mRNA has been considered as an attractive strategy for encoding a battery of proteins of interest. At Creative Biolabs, we have applied mRNA-based solutions to the unique challenge of the novel therapeutics’ development filed. Nowadays, we have generated a novel TriMix technology for boosting DC immune responses in a more potent, comprehensive, sustainable way. TriMix is a mixture of three types of mRNAs, which are responsible for encoding several immune-stimulating factors, such as CD40L, CD70, as well as TLR4. TLR4 stimulates DCs to present different types of antigens to CD4/CD8 T cells, CD40L induces CD4 T cells to initiate antigen-specific cell immunity, and CD70 induces CD8 T cell immune responses.
Recently, many studies conducted by our labs have indicated that TriMix can activate DC immunity and facilitate the interaction between DC pathways and different T cells. In recent studies, TriMix has been broadly used in the development of novel mRNA-based immunotherapy against various kinds of malignant tumors. The data have suggested that TriMix can strongly activate T cell responses against various tumor-associated antigens (TAAs). For instance, several TriMixs containing mRNA coding for specific tumor antigens have been designed as a perfect tool for inducing cytotoxic CD8 T cell responses in melanoma models. Besides, we have provided a wide range of TriMix assessment services to meet any special requirement of our clients, spanning from high-level corporate strategy development to detailed technical implementation.
With over years of experience in services of mRNA therapeutics development, Creative Biolabs offers a large collection of mRNA-based TriMix technology for different disease targets. Our client-focused, integrated team will anticipate challenges, overcome difficulties, and successfully convert various potential targets into commercial products. Please do not hesitate to contact us for more information.